Table 6.
Selected vaccine supply contracts for project BioShield
| Company | Product | Pathogen | Award (millions) | Date |
|---|---|---|---|---|
| Acambis | MVA3000 | Smallpox | $76.3 | 10/7/2004 |
| Modified vaccinia Ankara (MVA) attenuate vaccine | Smallpox | $10 | 02/25/2003 | |
| ACAM2000 clonal cell culture vaccine | Smallpox | $428 | 11/28/2001a | |
| Bavarian Nordic | Imvamune MVA | Smallpox | $100 | 10/07/2004 |
| Smallpox | $23b | 09/25/2003 | ||
| BioPort | Anthrax vaccine, 5-million doses | Bacillus anthracis | $122.7 | 05/06/2005 |
| DynaPort | Vaccine development, pilot production | Francisella tularemia | $35.1 | 10/05/2005 |
| Vaccine development | Francisella tularemia, Clostridium botulinum, Venezuelan equine encephalitis virus | $19.7 | 12/07/2004 | |
| Hepatavalent vaccine development | Clostridium botulinum | $11 | 09/04/2003 | |
| Live attenuated vaccine | Francisella tularemia | $4.6 | 10/07/2004 | |
| VaxGen | rPA102, 75 million doses | Anthrax | $877.5 | 11/04/2004 |
| rPA102, clinical trials | Anthrax | $80.3 | 09/02/2003 | |
| rPA102 | Anthrax | $11b (approximate) | 10/02/2002 |
Source: US Department of Health & Human Services.
aOriginal order for 209 million doses cut to 182.5 million doses.
bGrants shared by two companies, individual grant not disclosed.